FOSL1 and Miyoshi myopathy: HDAC inhibitors (HDACis) including valproic acid (VPA), vorinostat (SAHA), trichostatin A (TSA) and LBH589 suppress the transcription of both c-Jun and Fra-1 and thereby reduce c-Jun: Fra-1 heterodimer formation and activity [84], which may, at least in part, explain their anti-MM activity.